GARCEAU ROGER 4
4 · Protara Therapeutics, Inc. · Filed Jun 16, 2026
Research Summary
AI-generated summary of this filing
Protara (TARA) Director Roger Garceau Receives 31,000-Share Award
What Happened
- Roger Garceau, a director of Protara Therapeutics, received an award of 31,000 derivative shares on 2026-06-15. The transaction price is reported as $0.00, indicating an awarded grant rather than a market purchase or sale. This was reported on a Form 4 filed 2026-06-16.
Key Details
- Transaction type: Award/Grant (code A); derivative security.
- Transaction date: 2026-06-15; Form 4 filed: 2026-06-16 (filed within the typical 2-business-day window).
- Price: $0.00 per share (no cash paid by the insider).
- Shares subject to vesting: 31,000; vest in full on the first anniversary of the grant or upon a Change of Control, contingent on continued board service (footnote F1).
- Shares owned after the transaction: not specified in the filing.
Context
- This is a standard board compensation award (likely restricted stock or RSUs) and does not represent an open-market purchase or sale. Because the shares vest in the future, they are not immediately tradable and do not indicate an immediate personal liquidity event.
Insider Transaction Report
Form 4
GARCEAU ROGER
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-06-15+31,000→ 31,000 totalExercise: $3.94From: 2027-06-15Exp: 2036-06-14→ Common Stock (31,000 underlying)
Footnotes (1)
- [F1]1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Signature
/s/ Mary Grendell, Attorney-in-fact|2026-06-16